A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. However, the efficacy of EGFR-TKIs in wild-type (wt) EGFR tumours has been shown to be...

Full description

Bibliographic Details
Main Authors: Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2022-07-01
Series:Bioactive Materials
Subjects:
Non-small cell lung cancer
EGFR wild-Type
Superparamagnetic iron oxide
Erlotinib
Bevacizumab
Tumour vascular normalization
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X21005181

Internet

http://www.sciencedirect.com/science/article/pii/S2452199X21005181

Similar Items